Prescient Therapeutics (FRA:UDD) Other Long Term Assets: €0.24 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Prescient Therapeutics Other Long Term Assets?

Prescient Therapeutics FRA:UDD +4.92% Other Long Term Assets is €0.24 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Prescient Therapeutics's other long-term assets for the quarter that ended in Jun. 2026 was €0.24 Mil.

Prescient Therapeutics's quarterly other long-term assets declined from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then increased from Dec. 2025 (€0.00 Mil) to Jun. 2026 (€0.24 Mil).

Prescient Therapeutics's annual other long-term assets increased from Jun. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) and increased from Jun. 2025 (€0.00 Mil) to Jun. 2026 (€0.24 Mil).

Prescient Therapeutics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Other Long Term Assets Chart

Prescient Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.24

Prescient Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.24

Prescient Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €0.24 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Other Long Term Assets of €0.24 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Other Long Term Assets too high?
Prescient Therapeutics' current Other Long Term Assets is €0.24 Mil.
How does Prescient Therapeutics' Other Long Term Assets compare to VRTX and REGN?
Prescient Therapeutics' Other Long Term Assets of €0.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Other Long Term Assets is €0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Other Long Term Assets of €0.24 Mil. The current Other Long Term Assets is €0.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Other Long Term Assets is €0.24 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.